Header

UZH-Logo

Maintenance Infos

Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy


Abstract

This paper aims to provide an overview of the rationale and basic principles guiding the governance of genomic testing services, to clarify their objectives, and allocate and define responsibilities among stakeholders in a health-care system, with a special focus on the EU countries. Particular attention is paid to issues pertaining to pricing and reimbursement policies, the availability of essential genomic tests which differs between various countries owing to differences in disease prevalence and public health relevance, the prescribing and use of genomic testing services according to existing or new guidelines, budgetary and fiscal control, the balance between price and access to innovative testing, monitoring and evaluation for cost-effectiveness and safety, and the development of research capacity. We conclude that addressing the specific items put forward in this article will help to create a robust policy in relation to pricing and reimbursement in genomic medicine. This will contribute to an effective and sustainable health-care system and will prove beneficial to the economy at large.

Abstract

This paper aims to provide an overview of the rationale and basic principles guiding the governance of genomic testing services, to clarify their objectives, and allocate and define responsibilities among stakeholders in a health-care system, with a special focus on the EU countries. Particular attention is paid to issues pertaining to pricing and reimbursement policies, the availability of essential genomic tests which differs between various countries owing to differences in disease prevalence and public health relevance, the prescribing and use of genomic testing services according to existing or new guidelines, budgetary and fiscal control, the balance between price and access to innovative testing, monitoring and evaluation for cost-effectiveness and safety, and the development of research capacity. We conclude that addressing the specific items put forward in this article will help to create a robust policy in relation to pricing and reimbursement in genomic medicine. This will contribute to an effective and sustainable health-care system and will prove beneficial to the economy at large.

Statistics

Citations

Dimensions.ai Metrics
16 citations in Web of Science®
14 citations in Scopus®
10 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

143 downloads since deposited on 23 Feb 2017
39 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Public Health, Environmental and Occupational Health
Health Sciences > Genetics (clinical)
Language:English
Date:28 September 2016
Deposited On:23 Feb 2017 12:13
Last Modified:31 Jul 2020 00:54
Publisher:Karger
ISSN:1662-4246
OA Status:Hybrid
Publisher DOI:https://doi.org/10.1159/000449152
PubMed ID:27676083

Download

Hybrid Open Access

Download PDF  'Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy'.
Preview
Content: Published Version
Filetype: PDF
Size: 251kB
View at publisher